APAidan Pucchio

Aidan Pucchio

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aidan Pucchio has a total of 53 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Emergency physician-directed streamlined access to ophthalmology consultations: evaluation of a direct access pathway

    by Kristina Nazzicone, Kelly Ann Hutchinson, Aidan Pucchio, Mia Sams, Nirmay Shah, Mark Bona, Stephanie Baxter, Jacob Rullo, Rachel Curtis

  • Open Access

    Exploring vision tests as a surrogate for depression screening in patients with a visual impairment: A cross-sectional study

    by Karen Eden, Andrew G. Day, Aidan Pucchio, Rohit Shukla, Mark Bona

  • Applications of artificial intelligence and bioinformatics methodologies in the analysis of ocular biofluid markers: a scoping review

    by Aidan Pucchio, Saffire H. Krance, Daiana R. Pur, Jasmine Bhatti, Arshpreet Bassi, Karthik Manichavagan, Shaily Brahmbhatt, Ishita Aggarwal, Priyanka Singh, Aleena Virani, et al.

    Purpose This scoping review summarizes the applications of artificial intelligence (AI) and bioinformatics methodologies in analysis of ocular biofluid markers. The secondary objective was to explore supervised and unsupervised AI techniques and their predictive accuracies. We also evaluate the integration of bioinformatics with AI tools. Methods This scoping review was conducted across five electronic databases including EMBASE, Medline, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Web of Science from inception to July 14, 2021. Studies pertaining to biofluid marker analysis using AI or bioinformatics were included. Results A total of 10,262 articles were retrieved from all databases and 177 studies met the inclusion criteria. The most commonly studied ocular diseases were diabetic eye diseases, with 50 papers (28%), while glaucoma was explored in 25 studies (14%), age-related macular degeneration in 20 (11%), dry eye disease in 10 (6%), and uveitis in 9 (5%). Supervised learning was used in 91 papers (51%), unsupervised AI in 83 (46%), and bioinformatics in 85 (48%). Ninety-eight papers (55%) used more than one class of AI (e.g. > 1 of supervised, unsupervised, bioinformatics, or statistical techniques), while 79 (45%) used only one. Supervised learning techniques were often used to predict disease status or prognosis, and demonstrated strong accuracy. Unsupervised AI algorithms were used to bolster the accuracy of other algorithms, identify molecularly distinct subgroups, or cluster cases into distinct subgroups that are useful for prediction of the disease course. Finally, bioinformatic tools were used to translate complex biomarker profiles or findings into interpretable data. Conclusion AI analysis of biofluid markers displayed diagnostic accuracy, provided insight into mechanisms of molecular etiologies, and had the ability to provide individualized targeted therapeutic treatment for patients. Given the progression of AI towards use in both research and the clinic, ophthalmologists should be broadly aware of the commonly used algorithms and their applications. Future research may be aimed at validating algorithms and integrating them in clinical practice.


  • Open Access

    Response to Finsterer and Scorza

    by Marina I. Salvadori, Aidan Pucchio, Maya Heled Akiva, Helena Evangeliou, Jesse Papenburg

  • Development of a standardized Canadian undergraduate medical education ophthalmology curriculum

    by Charles Paco, Aidan Pucchio, Nawaaz Nathoo, Anuradha Mishra, Karim F. Damji, Christine Law


  • Anesthesia for ophthalmic surgery: an educational review

    by Aidan Pucchio, Daiana R. Pur, Anuradha Dhawan, Simrat K. Sodhi, Austin Pereira, Netan Choudhry

    Purpose Selecting an anesthetic agent for ophthalmic surgery has crucial implications for the surgeon, anesthesiologist, and patient. This educational review explores the common classes of anesthesia used in ophthalmology. Additionally, we discuss the considerations unique to cataract, glaucoma, strabismus, orbital, oculoplastic, and ocular trauma surgeries. Methods A comprehensive Embase search was performed using combinations of the subject headings “anesthesia”, “eye surgery”, “ophthalmology” and “cataract extraction”, “glaucoma”, “strabismus”, “vitreoretinal surgery”, “retina surgery”, “eye injury”, and “eyelid reconstruction”. Results Topical anesthetics are the most commonly used form of ocular anesthesia, used in both an office and surgical setting, and carry a minimal side effect profile. Notably, topical anesthetics offer analgesia, but do not provide akinesia or amnesia. Regional blocks, such as are sub-Tenon’s, peribulbar, and retrobulbar blocks, are used when akinesia is required in addition to analgesia. Recently, sub-Tenon’s blocks have recently gained popularity due to their improved safety profile compared to other regional blocks. General anesthesia is considered for long, complex surgery, surgery in patients with multiple comorbidities, surgery in young pediatric patients, or surgery in patients intolerant to local or regional anesthetic. Conclusion Anesthetizing the eye has rapidly evolved in recent years, supporting the safety, efficacy and comfort of ocular surgery. Since there are many viable options of anesthetics available for ophthalmic surgery, a robust understanding of the patients needs, the skill of the surgical team, and surgery-specific factors ought to be considered when creating an anesthetic plan for surgery.


  • Open Access

    The role of artificial intelligence in analysis of biofluid markers for diagnosis and management of glaucoma: A systematic review

    by Aidan Pucchio, Saffire Krance, Daiana R Pur, Arshpreet Bassi, Rafael Miranda, Tina Felfeli

    Purpose: This review focuses on utility of artificial intelligence (AI) in analysis of biofluid markers in glaucoma. We detail the accuracy and validity of AI in the exploration of biomarkers to provide insight into glaucoma pathogenesis. Methods: A comprehensive search was conducted across five electronic databases including Embase, Medline, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Web of Science. Studies pertaining to biofluid marker analysis using AI or bioinformatics in glaucoma were included. Identified studies were critically appraised and assessed for risk of bias using the Joanna Briggs Institute Critical Appraisal tools. Results: A total of 10,258 studies were screened and 39 studies met the inclusion criteria, including 23 cross-sectional studies (59%), nine prospective cohort studies (23%), six retrospective cohort studies (15%), and one case-control study (3%). Primary open angle glaucoma (POAG) was the most commonly studied subtype (55% of included studies). Twenty-four studies examined disease characteristics, 10 explored treatment decisions, and 5 provided diagnostic clarification. While studies examined at entire metabolomic or proteomic profiles to determine changes in POAG, there was heterogeneity in the data with over 175 unique, differentially expressed biomarkers reported. Discriminant analysis and artificial neural network predictive models displayed strong differentiating ability between glaucoma patients and controls, although these tools were untested in a clinical context. Conclusion: The use of AI models could inform glaucoma diagnosis with high sensitivity and specificity. While insight into differentially expressed biomarkers is valuable in pathogenic exploration, no clear pathogenic mechanism in glaucoma has emerged.


  • Open Access

    Severe rhabdomyolysis secondary to COVID-19 mRNA vaccine in a teenager

    by Aidan Pucchio, Maya Heled Akiva, Helena Evangeliou, Jesse Papenburg, Marina I. Salvadori

    Background Rhabdomyolysis, the breakdown of skeletal muscles following an insult or injury, has been established as a possible complication of SARS-CoV-2 infection. Despite being highly effective in preventing COVID-19-related morbidity and mortality, several cases of COVID-19 mRNA vaccination-induced rhabdomyolysis have been identified. We provide the second description of a pediatric case of severe rhabdomyolysis presenting after COVID-19 mRNA vaccination. Case: diagnosis/treatment A 16-year-old male reported to the emergency department with a 2-day history of bilateral upper extremity myalgias and dark urine 2 days after his first dose of COVID-19 vaccine (Pfizer-BioNtech). The initial blood work showed an elevated creatinine kinase (CK) of 141,300 units/L and a normal creatinine of 69 umol/L. The urinalysis was suggestive of myoglobinuria, with the microscopy revealing blood but no red blood cells. Rhabdomyolysis was diagnosed, and the patient was admitted for intravenous hydration, alkalinization of urine, and monitoring of kidney function. CK levels declined with supportive care, while his kidney function remained normal, and no electrolyte abnormalities developed. The patient was discharged 5 days after admission as his symptoms resolved. Conclusion While vaccination is the safest and most effective way to prevent morbidity from COVID-19, clinicians should be aware that rhabdomyolysis could be a rare but treatable adverse event of COVID-19 mRNA vaccination. With early recognition and diagnosis and supportive management, rhabdomyolysis has an excellent prognosis.


  • Validation of a microsurgical video-based scoring system for evaluating corneal suturing performance

    by Rachel Curtis, Aidan Pucchio, Wilma Hopman, Davin Johnson, Christine Law